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ardiac Allograft Vasculopathy
n Heart Transplant Patients
athologic and Clinical
spects for Angioplasty/Stenting*
on A. Kobashigawa, MD, FACC
os Angeles, California
he paper by Jonas et al. (1) in this issue of the Journal
llustrates the inflammatory nature of cardiac allograft vas-
ulopathy (CAV) in heart transplant recipients. The authors
eport that heart transplant patients who undergo coronary
rtery angioplasty/stent and subsequently develop in-stent
estenosis correspondingly develop worsening disease in
ther areas of the coronary artery tree. Therefore, in heart
ransplant patients, in-stent restenosis appears to be repre-
entative of a heightened immune response. In accordance
ith this finding, heart transplant patients with in-stent
estenosis, compared to those patients without restenosis,
ave increased subsequent mortality.
See page 453
Cardiac allograft vasculopathy is one of the major factors
imiting long-term survival in recipients of a heart trans-
lant. The disease has many features similar to non-
ransplant atherosclerosis, but there are important differ-
nces in both pathology and distribution of the disease.
ardiac allograft vasculopathy is thought to result from an
nitial injury to the allograft endothelium ensuing in a
hronic inflammatory state. Principal determinants contrib-
ting to this endothelial cell inflammation include preser-
ation injury, alloimmune response (cellular and humoral
ejection), and possibly chronic cytomegalovirus infection,
n addition to the conventional risk factors for atheroscle-
osis, such as hyperlipidemia. The general distinguishing
eature of CAV compared with conventional atherosclerosis
s its more diffuse nature, with frequent involvement of
arge- and medium-sized vessels as well as the microvascu-
ature. With CAV, lesions also tend to be concentric,
imiting detection by conventional angiography. For the
ost part, lesions tend to be lipid-poor, and calcification
eems to occur relatively late. The disease not only affects
he intima but also the media and adventitia, frequently
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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atory remodeling of the artery is inhibited (the Glagov
henomenon), and the artery may even undergo constric-
ion (2). Intravascular thrombus is also a frequent finding at
utopsy, which may explain why this disease is associated
ith sudden death. Clinical presentation of CAV is also
typical because of surgical denervation. Diagnosis and
onitoring of disease depends mostly on invasive tech-
iques. One of the more sensitive means to detect CAV is
he use of intravascular ultrasound (IVUS), which assesses
ntimal thickening and is performed at the time of coronary
ngiography.
The finding by Jonas et al. (1) that more inflammation in
he donor coronary arteries is associated with poor outcome
n heart transplant patients is exemplified in IVUS studies.
recent multicenter study of first-year IVUS data in heart
ransplant patients validated the use of first-year intimal
hickening as a surrogate marker for poor outcome after
eart transplantation (3). Development of intimal thicken-
ng0.5 mm in the first year after transplant conferred poor
urvival, more non-fatal major adverse cardiac events, and
ore angiographic CAV in 5-year follow-up. The rapid
rogression in first-year intimal thickening as detected by
VUS appears to represent the cumulative effects of adverse
vents that cause damage and inflammation to the coronary
rtery endothelial cells, which ultimately lead to poor
linical outcome.
In order to effectively treat CAV, as suggested by Jonas et
l. (1), a global approach to reducing inflammation in all
reas of the donor coronary artery tree is essential. This will
nvolve newer immunosuppressive agents that can alter the
mmune response in the heart transplant recipient. Many of
he heart transplant multicenter, randomized trials testing
hese newer immunosuppressive agents have utilized first-
ear IVUS intimal thickening as a study end point to predict
he development of CAV and long-term outcomes. Re-
ently, newer antiproliferative agents, including sirolimus
4), everolimus (5), and mycophenolate mofetil (6), have
een demonstrated to significantly reduce first-year rejec-
ion and IVUS intimal thickening in large, multicenter,
andomized trials involving heart transplant patients.
onger follow-up of these study populations will be needed
o confirm the actual efficacy of these antiproliferative
gents in reducing angiographic CAV.
Hyperlipidemia is a well-established risk factor for non-
ransplant atherosclerosis. Both clinical and experimental
bservations suggest that it may be important in the
evelopment of CAV (7). Interestingly, a randomized trial
eported that treatment initiated within 2 weeks of trans-
lantation with an inhibitor of the rate-limiting enzyme in
he cholesterol biosynthetic pathway, hydroxymethylglutryl
oenzyme A (HMG Co-A) reductase, is associated not only
ith decreased development of coronary artery intimal
hickening, but also with decreased clinically severe rejec-
ion, decreased development of angiographic CAV, and
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August 1, 2006:462–3 Editorial Commentmproved survival (8). These agents likely have an anti-
nflammatory and/or immunosuppressive effect in addition
o their lipid-lowering activity (9). Moreover, HMG Co-A
eductase inhibitors have been demonstrated to reduce
igh-sensitivity C-reactive protein, a known marker of
nflammation that has been associated with both non-
ransplant and transplant atherosclerosis (10). As hyperlip-
demia is so common after transplantation, these findings
uggest that all cardiac transplant recipients should receive
MG Co-A reductase inhibitors where tolerated.
It is clear that angioplasty/stenting can be performed with
high success rate in heart transplant patients. However,
rom the results of the Jonas et al. (1) study, the long-term
enefit of performing angioplasty/stenting for all CAV
esions amenable to this procedure is not clear. Does this
rocedure prolong survival or decrease non-fatal major
dverse cardiac events? Are there subgroups of specific CAV
esions, such as left main or proximal left anterior descend-
ng artery stenoses, where benefit is greater? If in-stent
estenosis is a marker for a heightened inflammatory state of
he donor coronary artery tree, is it worth redoing this
rocedure, especially since worsening CAV occurs in other
reas and subsequent mortality is high? It might be time to
erform a randomized trial of angioplasty/stenting in heart
ransplant patients with significant CAV.
Given the relatively poor prognosis of CAV, prevention
emains an important strategy. Greater understanding of the
athology of CAV will offer more promising immunosup-
ressive regimens and improved methods of organ preser-
ation in the near future. It is hoped that this will have a
ignificant impact on the development of CAV in the heart
ransplant population. In the meantime, those with estab-
ished disease have conventional revascularization tech-iques available to them for palliation, and retransplantation
ay be a consideration for a few.
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